Press Releases

Press Releases

All Releases
Sep 16, 2014
- Presentation Will Occur at the 2014 American Academy of Ophthalmology Annual Meeting - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that a subgroup analysis assessing the development and progression of sub-retinal fibrosis in the Company's Phase 2b trial
Sep 08, 2014
- Initial Milestone Payment Triggered by Reaching First Enrollment Goal in the Fovista ® Phase 3 Program - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the
Sep 02, 2014
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Morgan Stanley Global Healthcare Conference
Aug 06, 2014
- Conference Call and Webcast, Today, August 6 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today provided an update on the Company's business and announced financial results for the second quarter ended June 30, 2014 .
Aug 05, 2014
- First Patient Dosed in an Open-Label Study in Ophthotech's Anti-Fibrosis Program - - Fovista ® Combination Therapy Phase 2b Subgroup Analysis for Reduction of Sub-retinal Fibrosis to be Presented at the 2014 Annual Meeting of the American Academy of Ophthalmology - NEW YORK --(BUSINESS
Jul 29, 2014
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the second quarter ended June 30, 2014 , on Wednesday, August 6, 2014 . Following the announcement, Ophthotech's management will host a live conference call and webcast
May 19, 2014
- Ophthotech to Potentially Receive Over $1 Billion , Inclusive of $330 Million in an Upfront Fee ( $200 Million ) and Near-term Enrollment Milestones ( $130 Million ), Not Including Future Royalties - - Ophthotech Grants Ex-US Commercialization Rights to Fovista ® while Retaining Sole US
May 13, 2014
- Conference Call and Webcast, Today, May 13 , at 8:00 a.m. ET - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the first quarter ended March 31, 2014 and provided an update on the Company's business including its product development
May 08, 2014
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the first quarter ended March 31, 2014 , on Tuesday, May 13, 2014 . Following the announcement, Ophthotech's management will host a live conference call and webcast at
Mar 05, 2014
Webcast Available Through Ophthotech Website NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Barclays Capital Global Healthcare Conference
Mar 04, 2014
-Webcast to Begin at 8:30 a.m. Eastern time - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that the Company will host a live webcast in conjunction with its Research and Development (R&D) Day on Friday, March 7, 2014 , beginning at 8:30 a.m. ET.
Feb 27, 2014
Conference Call and Webcast Today, February 27 , at 8:00 a.m. ET NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development
Feb 24, 2014
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that its fourth quarter and year ended December 31, 2013 , financial results will be released on Thursday, February 27, 2014 . Following the announcement, Ophthotech's management will host a live conference call and
Feb 18, 2014
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today the closing of its previously announced registered public offering of 2,628,571 shares of its common stock at a price to the public of $31.50 per share, before underwriting discounts.
Feb 11, 2014
New York, NY— Feb. 11, 2014 —Ophthotech Corporation (NASDAQ: OPHT) announced today the pricing of an underwritten public offering of 2,285,714 shares of common stock at a public offering price of $31.50 per share, before underwriting discounts.
Feb 10, 2014
Ophthotech Corporation Announces Proposed Public Offering of Common Stock New York, NY-Feb. 10, 2014 -Ophthotech Corporation (NASDAQ: OPHT) announced today that it has commenced an underwritten public offering of 1,900,000 shares of its common stock. In addition, certain stockholders of the company
Jan 24, 2014
Ophthotech Corporation Receives $41.7 Million in Second Tranche in Royalty Financing from Novo A/S New York, NY—January 24, 2014 —Ophthotech Corporation (Nasdaq: OPHT) today announced that it has received payment of approximately $41.7 million in a second tranche in royalty financing
Oct 30, 2013
Ophthotech to Report Third Quarter 2013 Results and Host Conference Call on Wednesday, November 13, 2013 NEW YORK, NY – October 30, 2013 – Ophthotech Corporation (Nasdaq: OPHT) today announced that the company will report its financial results for the third quarter ended September 30,